Association of Metabolic Syndrome and Hyperferritinemia in Patients at Cardiovascular Risk

Ricardo José Tofano,1,2 Leticia Maria Pescinni-Salzedas,1 Eduardo Federighi Baisi Chagas,2 Claudia Rucco Penteado Detregiachi,2 Elen Landgraf Guiguer,1– 3 Adriano Cressoni Araujo,1,2 Marcelo Dib Bechara,1 Claudio José Rubira,1 Sandra Maria Barbalho1– 3 1Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Marília, São Paulo, Brazil; 2Postgraduate Program in Structural and Functional Interactions in Rehabilitation, UNIMAR, Marília, São Paulo, Brazil; 3School of Food and Technology of Marilia (FATEC), Marilia, São Paulo, BrazilCorrespondence: Sandra Maria BarbalhoDepartment of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Av. Higino Muzzi Filho 1001, Marília 15525-902, São Paulo, BrazilTel +55 14 99655-3190Email smbarbalho@gmail.comAim: To evaluate the association between parameters of hyperferritinemia (HF) and metabolic syndrome (MS) in patients at cardiovascular risk.Patients and Methods: This is a cross-sectional analytical observational study that included 269 patients who attended a cardiology unit. Biochemical and anthropometric parameters were evaluated to identify the presence of HF and MS. The presence of MS was evaluated according to NCEP ATP III. Biochemical parameters (glycemia, triglycerides, HDL-c) were assessed according to the manufacturer’s protocols. Anthropometric measurements and blood pressure measurements were made by a trained professional. The chi-square (X2) test, odds ratio, normality distribution (verified by the Kolmogorov–Smirnov test), and Levene’s test were used to analyze the variables. To evaluate the effect of MS, HF, and the interaction between MS and HF, two-way analysis of variance (ANOVA) was performed based on the homogeneity of the variances, followed by Bonferroni’s pos